QuidelOrtho Corp
No SEC Form 4 filings for $QDEL in the last 30 days.
QuidelOrtho (QDEL) shares fell 21.3% after the company cut its full-year revenue and adjusted EPS outlook, despite a Q2 beat. Q2 revenue was $630.9 million and adjusted EPS $0.13. Full-year revenue guidance was lowered to $2.52 billion to $2.6 billion and adjusted EPS to $0.65 to $0.90, below prior estimates.
QuidelOrtho (NASDAQ: QDEL) reported Q2 CY2026 revenue of $630.9 million, up 2.8% year on year and above analysts’ estimates, and non-GAAP EPS of $0.13, above consensus. Full-year revenue guidance was $2.56 billion at the midpoint, 5.4% below estimates. The stock fell 21.6% to $12.80 after results, citing China demand headwinds.
QuidelOrtho Corp (QDEL) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 qdel6282026ex991earningsre.htm EX-99.1 Document Exhibit 99.1 QuidelOrtho Reports Second Quarter 2026 Financial Results ― Total revenue grew 3% reported and 2% constant currency, primarily driven by Labs and Point of Care growth― ― Excluding China, total revenue grew 6%
Over the past 7 days, alphai's AI scored 4 news stories mentioning QDEL (QuidelOrtho Corp). Coverage has skewed bearish: 0 bullish, 1 neutral, and 3 bearish.
Recent QDEL coverage spans earnings, financial news and corporate actions.
The guidance cut is the dominant driver, signaling weaker forward demand and pressuring valuation multiples.
The quarter beat on revenue and non-GAAP EPS, but the full-year revenue guidance miss and margin deterioration drove a sharp selloff.
Guidance reset and FCF guidance withdrawal increase downside risk to 2026 earnings quality and cash conversion, while ex-China growth partially offsets.
Earnings timing and the setup from the prior quarter’s revenue and EPS misses create a near-term catalyst, but the article provides no new guidance or print.
Unit-sale exploration is a potential value-realization catalyst, but it is rumor-based and may not translate into a signed deal.
alphai scores every news story that mentions QDEL with an AI model for sentiment and relevance, and aggregates insider trades from QuidelOrtho Corp's SEC EDGAR Form 4 filings. Figures refresh continuously.
QuidelOrtho (QDEL) shares fell 21.3% after the company cut its full-year revenue and adjusted EPS outlook, despite a Q2 beat. Q2 revenue was $630.9 million and adjusted EPS $0.13. Full-year revenue guidance was lowered to $2.52 billion to $2.6 billion and adjusted EPS to $0.65 to $0.90, below prior estimates.
4 min readQuidelOrtho (NASDAQ: QDEL) reported Q2 CY2026 revenue of $630.9 million, up 2.8% year on year and above analysts’ estimates, and non-GAAP EPS of $0.13, above consensus. Full-year revenue guidance was $2.56 billion at the midpoint, 5.4% below estimates. The stock fell 21.6% to $12.80 after results, citing China demand headwinds.
4 min readQuidelOrtho Corp (QDEL) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 qdel6282026ex991earningsre.htm EX-99.1 Document Exhibit 99.1 QuidelOrtho Reports Second Quarter 2026 Financial Results ― Total revenue grew 3% reported and 2% constant currency, primarily driven by Labs and Point of Care growth― ― Excluding China, total revenue grew 6%
3 min readQuidelOrtho (QDEL) will report earnings Thursday after the bell. The company missed last quarter’s revenue expectations, with revenue of $619.8M, down 10.5% YoY, and also missed EPS guidance and EPS estimates. For this quarter, analysts expect revenue flat YoY. QDEL is down 2.4% over the past month versus an average peer gain; average analyst price target is $21.33 vs $17.58.
3 min readBiotech gainers highlighted: Universe Pharma (UPC) surged 311% after agreeing to buy Best Praise International for $10.75M in shares to expand its China patent portfolio; Decoy Therapeutics (DCOY) rose 74% on a PIPE up to $21M; QuidelOrtho (QDEL) gained 32% on reports it may sell its point-of-care unit for about $1.5B; SELLAS (SLS) jumped 25% ahead of AML trial readouts.
6 min readQuidelOrtho Corp (QDEL) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. qdel-20260622 0001906324 false 0001906324 2026-06-22 2026-06-22 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported):
3 min readQuidelOrtho (Nasdaq: QDEL) appointed Micah Young as Chief Financial Officer effective July 6, 2026, succeeding Joseph M. Busky, who will retire and remain as an adviser during the transition. Young most recently served as CFO at Masimo. The company said the move supports efforts to improve profitability, cash generation, and execution.
2 min readQuidelOrtho Corp (QDEL) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K QuidelOrtho Corp false 0001906324 0001906324 2026-06-16 2026-06-16 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event rep
2 min readQuidelOrtho (Nasdaq: QDEL) and the Allo Hope Foundation announced a collaboration to improve prenatal care for pregnancies affected by maternal red blood cell alloimmunization. The groups plan co-produced educational materials and early testing/connection efforts for lab technicians, clinicians and families, starting this summer, via their digital channels. The aim is to help address risks of HDFN by improving timely, informed care.
3 min readMcIntyre Partnerships’ Q1 2026 investor letter said its fund fell 19% gross and 20% net, citing a broad pullback in life science tools/medical device stocks and stock-specific issues at QuidelOrtho (QDEL). The fund reported 123% long, 27% short, and 97% net exposure by month-end; QDEL was its largest position. QDEL closed at $13.02 on May 29, 2026; the firm reported $620 million revenue in Q1 2026.
6 min read
